Journal of Allergy and Clinical Immunology
HAE Attack Reduction With BW-20805
Zhi Y, Zhao X, Zhu R, et al
This open-label, multicenter phase 2 study evaluated the efficacy and safety of BW-20805, a long-acting siRNA targeting plasma prekallikrein, in adults with hereditary angioedema (HAE) across multiple dosing regimens. BW-20805 produced substantial and sustained reductions in HAE attack rates, with many patients becoming attack-free and marked suppression of prekallikrein levels, supporting strong biologic activity. BW-20805 was generally well tolerated and demonstrated durability consistent with infrequent dosing up to every 3–6 months, supporting its potential as a long-acting prophylactic treatment for HAE.
Previous Article
- • Attack Rate Reductions After Berotralstat Initiation Among Patients With Hereditary Angioedema
- • Navenibart Delays Time to First HAE Attack
- • APG777 in Patients With Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities
- • Skin Lipid Biomarkers for Prediction of Atopic Dermatitis and Food Allergy Risk
- • Fel d 1-Expressing Plant-Derived Bioparticle for CAT Allergy
- • Dietary Consumption Feasibility Following Treatment With Multi-Food Oral Immunotherapy or Omalizumab
- • Remibrutinib Provides Fast Symptom Relief in the Pooled REMIX-1/-2 Studies
- • Real-Time AI Identification and Quantification of Airborne Pollen Species
- • Artificial Intelligence vs Board-Certified Allergist/Immunologists: Responses to Food Allergy Questions
- • HLA-A*32:01 Carriage Is Associated With Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms
- • Microbiome Associations With Food Sensitization in the ACTIVATE Trial
- • Exposure to Vaginal Microbiome in C-Section Infants at High Risk for Allergies
- • RAPIDe-3: Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema
- • Oral Deucrictibant Improves Health-Related Quality of Life in Participants With Hereditary Angioedema
- • Hereditary Angioedema Attacks With Sebetralstat in the KONFIDENT-S Study
- • HAE Attack Reduction With BW-20805
- • Phase 1b/2 Trial of Navenibart for Hereditary Angioedema
- • Phase 2 Results: LP-003 Significantly Decreases Chronic Spontaneous Urticaria Disease Activity
- • Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
- • Dose-Finding Study of Barzolvolimab in Patients With Chronic Spontaneous Urticaria
- • The Phase 2 APEX Study of APG777 in Atopic Dermatitis
- • The Gut–Skin Axis in Vietnamese Children With Atopic Dermatitis
- • STMC-103H Reduces Risk of Atopic Dermatitis and Food Allergy in At-Risk Infants
- • Biomarker Discovery for Food Allergy Using Artificial Intelligence
- • REGN1908-1909 Suppresses Cat-Allergen Induced Allergic Conjunctivitis and Skin Test Reactivity
- • The COMBINE Trial: Dupilumab Enhances Desensitization and Reduces GI Symptoms
- • Novel Technique for Measuring Fungal Function in Dust
- • Pet Sensitization Impacts on Asthma Exacerbations
- • Risk of Respiratory Tract Infections with Asthma Biologics
- • GLP-1 Receptor Agonists Reduce Asthma Exacerbations In Obese Type 2 Diabetics
